EDWARDS LIFESCIENCES EDWARDS INSPIRIS RESILIA AORTIC VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE
|
Back to Search Results |
|
Model Number 11500A |
Device Problems
Fluid/Blood Leak (1250); Gradient Increase (1270); Patient-Device Incompatibility (2682); Insufficient Information (3190); Patient Device Interaction Problem (4001)
|
Patient Problems
Heart Failure/Congestive Heart Failure (4446); Insufficient Information (4580)
|
Event Date 02/13/2023 |
Event Type
Injury
|
Manufacturer Narrative
|
The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
|
Event Description
|
Through implant patient registry it was learned that a 21mm 11500a aortic valve was explanted after an implant duration of 2 years, 8 months due to unknown reason.The explanted valve was replaced with a 25mm 3300tfx aortic valve.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members) and is not received in the form of a conventional customer complaint.The information reported may or may not be related to the edwards device.
|
|
Event Description
|
Through implant patient registry it was learned that a 21mm 11500a aortic valve was explanted after an implant duration of 2 years, 8 months due to moderate pannus and leaflet thrombosis.The patient presented with chf and doe.The explanted valve was replaced with a 25mm 3300tfx aortic valve.Per medical records, cardiac workup revealed aortic stenosis, mild mitral stenosis, and mild mitral regurgitation.The patient was suspected to have patient-prosthesis mismatch.The patient underwent redo modified konno-bentall with limited septal myectomy and laa clipping.Post cpb tee showed well seated replacement valve.The patient tolerated the procedure well with no complications.Pathology samples from the explanted valve showed moderate pannus on the inflow aspect of the valve, with leaflet thrombosis.The patient was discharged from the hospital on pod# 10.
|
|
Manufacturer Narrative
|
Updated sections: b5, b7, g3, g6, h6 component code, health effect - clinical code, device code(s), and type of investigation.
|
|
Manufacturer Narrative
|
The device history record was reviewed and shows that this device met all manufacturing specifications for product release prior to distribution.No issues were identified that would have impacted this event.Pannus overgrowth, or host tissue, is considered to be a form of non-structural valve dysfunction.The growth of host tissue on the sewing ring is expected and is a natural part of the healing reaction to prosthesis implantation.Pannus can have both beneficial and harmful effects depending on the amount of growth.A small amount of host tissue growth over the suture line is needed to form a non-thrombogenic surface and complete the healing process after valve implantation.In contrast, if there is an excessive amount of pannus growth, it can extend onto the cusp surfaces leading to thickening of the cusps, leaflet immobility, elevated gradients, and stenosis.Host tissue growth can also contribute to cusp retraction or curling resulting in valvular regurgitation.Thrombosis is a well-recognized complication of prosthetic devices.Device thrombosis is the formation of blood clots forming on the device/graft.These clots could significantly impact the function of the valve resulting in harm.There may be cases of incidental finding by imaging (echocardiography and/or ct scan) of subclinical leaflet thrombosis (halt) where the patient will benefit from a close follow-up and may be treated with oral anticoagulant.Through further investigation, it was determined that the root cause of this event was most likely due to patient related factors.
|
|
Search Alerts/Recalls
|
|
|